Sort
64,565 grants matching “drug discovery”
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ
$840,469Jian Li · Monash University · R01 · FY2020 · AI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
$840,301Daniel Hal Solomon · Brigham And Women'S Hospital · R01 · FY2017 · HL
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.
$840,205Sung Ok Yoon · Ohio State University · R01 · FY2018 · AG
Targeting RAGE-mDia1 in Diabetic Complications: Mechanisms and Therapeutics
$840,191Ann Marie Schmidt · New York University School Of Medicine · R24 · FY2014 · DK
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
$840,040Yuanpu Peter Di · Florida International University · R01 · FY2025 · AI
Genetics of novelty seeking and propensity for drug abuse in outbred rats
$840,034Huda Akil · University Of Michigan At Ann Arbor · U01 · FY2025 · DA
Enabling the study of endogenous proteins in live cells
$840,000Alice Y Ting · Massachusetts Institute Of Technology · DP1 · FY2008 · OD
Development of a charge-sensitive optical detection system for high-throughput study of small molecules
$839,999Nguyen Ly · Biosensing Instrument, Inc. · R44 · FY2021 · GM
Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease
$839,712Marwan Noel Sabbagh · Banner Sun Health Research Institute · R01 · FY2010 · AG
Interdepartmental Biotechnology Training Program
$839,572Karl D Wittrup · Massachusetts Institute Of Technology · T32 · FY2011 · GM
Drug Discovery for Chagas Disease
$839,338Frederick Simmons Buckner · University Of Washington · R01 · FY2024 · AI
Drug Discovery for Chagas Disease
$839,338Frederick Simmons Buckner · University Of Washington · R01 · FY2025 · AI
Targeting Mutant KRAS for Cancer Therapy
$839,300Said M Sebti · Virginia Commonwealth University · R35 · FY2021 · CA
Discovery Proteomics Core
$839,271Tukiet T Lam · Yale University · P30 · FY2025 · DA
Targeting Myosin to Treat Polycystic Kidney Disease
$839,264Benjamin Solomon Freedman · Plurexa Llc · R42 · FY2025 · DK
Xavier RCMI Renewal Application-Research Infrastructure Core
$839,216Vladimir Kolesnichenko · Xavier University Of Louisiana · U54 · FY2022 · MD
Development of Novel Therapeutics for Methamphetamine Abuse
$839,154Linda P Dwoskin · University Of Kentucky · U01 · FY2019 · DA
Functionally Validated Lentiviral siRNA libraries
$839,064Alex Chenchik · Cellecta, Inc. · R44 · FY2010 · RR
Probing Neuropsychiatric Diseases Using Targeted Epigenome and Genome Engineering
$839,050Feng Zhang · Broad Institute, Inc. · DP1 · FY2013 · MH
Mouse Models of Human Cancer Database
$839,047Carol J Bult · Jackson Laboratory · R01 · FY2025 · CA
A new genetic approach for studying prions and other pathogenic protein aggregate
$839,025Ann Hochschild · Harvard Medical School · DP1 · FY2012 · AI
A new genetic approach for studying prions and other pathogenic protein aggregate
$839,025Ann Hochschild · Harvard Medical School · DP1 · FY2011 · OD
Inhibitors of poxvirus enzymes as novel drugs
$839,005Esteban Edward Mena · Lifepharms, Inc. · U01 · FY2006 · AI
Mechanisms of FGF Receptor Regulation and Signaling
$838,937Moosa Mohammadi · New York University School Of Medicine · R01 · FY2014 · DE
Regulatory T Cells in Autoimmune Disease
$838,927David A. Hafler · Brigham And Women'S Hospital · U19 · FY2009 · AI